The estimated Net Worth of Robert L Erwin is at least $497 Mille dollars as of 4 June 2020. Mr. Erwin owns over 28,268 units of iBio Inc stock worth over $205,405 and over the last 13 years he sold IBIO stock worth over $0. In addition, he makes $291,751 as President at iBio Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Erwin IBIO stock SEC Form 4 insiders trading
Robert has made over 2 trades of the iBio Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 28,268 units of IBIO stock worth $26,289 on 4 June 2020.
The largest trade he's ever made was exercising 96,124 units of iBio Inc stock on 2 June 2020 worth over $89,395. On average, Robert trades about 15,549 units every 0 days since 2011. As of 4 June 2020 he still owns at least 108,108 units of iBio Inc stock.
You can see the complete history of Mr. Erwin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Erwin biography
Robert L. Erwin serves as President of the Company. Mr. Erwin has been our President since we became a publicly traded company in August 2008. Mr. Erwin led Large Scale Biology Corporation from its founding in 1988 through 2003, including a successful initial public offering in 2000, and continued as non-executive Chair until 2006. He served as Chair of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006. Mr. Erwin recently served as Managing Director of Bio-Strategic Directors LLC, providing consulting services to the life sciences industry. He is currently Chair of Novici and a Director of Oryn Therapeutics. Mr. Erwin’s non-profit work focuses on applying scientific advances to clinical medicine, especially in the field of oncology. He is co-founder, President and Director of the Marti Nelson Cancer Foundation, Oncology. Mr. Erwin received his BS degree with Honors in Zoology and an MS degree in Genetics from Louisiana State University.
What is the salary of Robert Erwin?
As the President of iBio Inc, the total compensation of Robert Erwin at iBio Inc is $291,751. There are 5 executives at iBio Inc getting paid more, with Thomas Isett having the highest compensation of $1,784,020.
How old is Robert Erwin?
Robert Erwin is 67, he's been the President of iBio Inc since 2008. There are 6 older and 9 younger executives at iBio Inc. The oldest executive at iBio Inc is Seymour Flug, 84, who is the Independent Director.
What's Robert Erwin's mailing address?
Robert's mailing address filed with the SEC is C/O NOVICI BIOTECH LLC, 3333 VACA VALLEY PARKWAY, VACAVILLE, CA, 95688.
Insiders trading at iBio Inc
Over the last 14 years, insiders at iBio Inc have traded over $99,626,328 worth of iBio Inc stock and bought 15,716,013 units worth $10,660,994 . The most active insiders traders include Capital Ltd Portfolio Servi..., Carl Desantis e William D Clark. On average, iBio Inc executives and independent directors trade stock every 98 days with the average trade being worth of $1,893,515. The most recent stock trade was executed by Martin Brenner on 1 November 2023, trading 4,881 units of IBIO stock currently worth $1,318.
What does iBio Inc do?
ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.
What does iBio Inc's logo look like?
Complete history of Mr. Erwin stock trades at iBio Inc
iBio Inc executives and stock owners
iBio Inc executives and other stock owners filed with the SEC include:
-
Thomas Isett,
Chairman of the Board, Chief Executive Officer -
Thomas F. Isett III,
CEO, Pres & Chairman -
Robert Kay,
Interim Secretary, Interim Treasurer, Director -
Randy Joe Maddux,
Chief Operating Officer -
Dr. Martin B. Brenner D.V.M., Ph.D.,
Chief Scientific Officer -
Robert Erwin,
President -
Robert B. Kay,
Interim Sec. & Interim Treasurer -
James Hill,
Independent Director -
John McKey,
Independent Director -
Seymour Flug,
Independent Director -
Glenn Chang,
Independent Director -
Stephen Kilmer,
Investor Relations -
Gary Sender,
Independent Director -
Alexandra Kropotova,
Independent Director -
Linda Armstrong,
Independent Director -
John Delta,
Principal Financial Officer, Principal Accounting Officer -
Carlos Picosse,
Chief Exec. Officer of IBio Brazil -
Dr. Melissa Berquist Ph.D.,
VP and Head of Vaccines & Animal Health -
Lisa Middlebrook,
Chief HR Officer -
Robert Matthew Lutz,
Chief Financial & Bus. Officer -
Mark A Giannone,
Chief Financial Officer -
Kenneth Bryan Dart,
10% owner -
Carl Desantis,
10% owner -
Philip K. Russell,
Director -
Arthur Y Elliott,
Director -
Capital Ltd Portfolio Servi...,
-
Ryan E Terence,
Chief Scientific Officer -
Randy Joe Maddux,
Chief Operating Officer -
Robert Matthew Lutz,
See Remarks -
James P. Mullaney,
Chief Financial Officer -
Evert B. Schimmelpennink,
Director -
E Gerald Kay,
10% owner -
Jules A. Musing,
Director -
William D Clark,
Director -
Martin Brenner,
See Remarks -
Felipe Duran,
Chief Financial Officer